Status:
COMPLETED
A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Thrombelastography,Acute on Chronic Liver Failure, Platelet
Eligibility:
All Genders
18-80 years
Brief Summary
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and prov...
Eligibility Criteria
Inclusion
- patient with previously diagnosed or undiagnosed HBV related chronic liver disease/cirrhosis
- INR≥1.5 and total bilirubin≥85μmol/L
Exclusion
- INR≤1.5 or total bilirubin≤85μmol/L;
- underlying chronic liver disease was other than chronic HBV infection related;
- those who had hepatocellular carcinoma or other types of malignancies;
- obstructive biliary diseases or other disease lead to bilirubin evaluation;
- those who had acute hemorrhage one week before admission
- those who received platelet, cryo transfusion or plasmapheresis one week before admission
- using steroid or immunosuppressant or antiplatelet or anticoagulant drugs in 4 weeks
- any kind of decompensation which persisted over a month
- pregnancy and breastfeeding
- those who received liver transplantation or kidney transplantation;
- combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2\<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS\<8)
- readmission;
- death within 24 hours.
Key Trial Info
Start Date :
October 30 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 13 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03281278
Start Date
October 30 2017
End Date
August 13 2018
Last Update
June 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital
Guangzhou, Guangdong, China, 510515